Arch Therapeutics 5/23/2023 Earnings Report

Arch Therapeutics EPS Results

• Actual EPS: $0.21
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Arch Therapeutics Revenue Results

• Actual Revenue: $0.02 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Arch Therapeutics Announcement Details

• Date: 5/23/2023
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Arch Therapeutics (OTCMKTS:ARTH) is a medical device company focused on designing and commercializing synthetic self-assembling peptide technologies to address unmet needs in surgical, wound care and emergency medicine. The company’s proprietary platform, known as AC5®, leverages short-chain peptides that rapidly form an extracellular matrix–like hydrogel upon contact with physiological fluids. This material is being developed to achieve hemostasis, seal tissue, and promote healing in a wide range of clinical settings.

Arch Therapeutics’ lead product candidate is AC5 Surgical Hemostatic Device, which aims to control non‐compressible bleeding during surgical procedures. Additional applications of the AC5 technology include an advanced wound care formulation for chronic wounds and a pulmonary sealant designed to manage air leaks following thoracic surgery. The company’s research and development efforts are centered on advancing these products through preclinical studies and regulatory pathways toward clinical use.

Founded in the mid-2000s and headquartered in Framingham, Massachusetts, Arch Therapeutics operates primarily in the United States, with strategic partnerships under exploration in Europe and Asia to extend its global reach. The company maintains collaborations with leading academic institutions and contract research organizations to support its pipeline development. Arch Therapeutics is led by a management team and board of directors with extensive experience in biotechnology, medical device commercialization and regulatory affairs, reflecting a commitment to translating innovative science into practical clinical solutions.